Skip to content
Unrated Drug recall · FDA · Published December 16, 2022

Aurolife Glycopyrrolate Tablets Recall: Failed Impurities Risk

Aurolife Pharma recalls 1 mg Glycopyrrolate tablets (NDC 13107-014-01) due to failed impurities tests. These prescription drugs may have harmful levels of impurities that could affect safety.

🇺🇸 FDA recall #D-0087-2023DrugAurolife ›
Take action

Contact the company

Recalling firmAurolife Pharma, LLC2400 US Highway 130 · Dayton, NJ 08810-1519
✎ GovInfoNow plain-language explainer

Aurolife Pharma is recalling prescription Glycopyrrolate tablets that failed impurities testing. This could mean the tablets contain harmful levels of impurities that might affect your safety when taken as directed. Read more at govinfonow.com/recall/34177-aurolife-glycopyrrolate-tablets-recall-failed-impurities-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/34177-aurolife-glycopyrrolate-tablets-recall-failed-impurities-risk · Updated August 18, 2026 · FDA enforcement record: FDA #D-0087-2023

Cite this page

“Aurolife Glycopyrrolate Tablets Recall: Failed Impurities Risk.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/34177-aurolife-glycopyrrolate-tablets-recall-failed-impurities-risk. Based on FDA recall #D-0087-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0087-2023%22&limit=1).

The FDA announced on 2022-12-16 that Aurolife Pharma, LLC is recalling Glycopyrrolate Tablets, USP, 1 mg due to failed impurity specifications. The recall affects lots distributed nationwide.

How to tell if you have it

  • Brand: Aurolife
  • Product: Glycopyrrolate Tablets, USP, 1 mg, 100 tablets, Rx Only
  • Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ
  • NDC: 13107-014-01
  • Lots: 01422002A1 (Expiry: 12/2023), 01421078A3 (Expiry: 09/2023)
  • Quantity: 7344 bottles
  • Distribution: Nationwide in the USA and Puerto Rico

The hazard

The tablets failed impurity specifications, according to the FDA. The agency classified the recall as Class II.

Context

GovInfoNow's records show Aurolife Pharma, LLC has 3 other recalls on record since 2019-08-23. Other recent recalls of similar products include Novadoz Glycopyrrolate Oral Solution Recall (2025-12-15), Precision Dose Glycopyrrolate Oral Solution Recall (2026-07-14), and Glenmark Alyacen Birth Control Tablets Recall (2026-05-27).

How to tell if you have this one

Check your prescription bottle for the brand 'Aurolife' and the specific lot numbers: 01422002A1 (expiring 12/2023) or 01421078A3 (expiring 09/2023).

  • Brand
    Aurolife
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Your Medication

    Look for the lot numbers 01422002A1 (expiring 12/2023) or 01421078A3 (expiring 09/2023) on your prescription bottle.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “Nationwide in the USA and Puerto Rico.” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA published this recall 12 days after the firm started it.

1. Firm started the recall: Dec 16, 202212. FDA classified it Class II: Dec 22, 202223. Published in FDA’s Enforcement Report: Dec 28, 202232022
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0087-2023 (December 16, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0087-2023 to see it in context.
  • Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA